Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Algeta ASA
Headquarters: Oslo, Norway
Website: N/A
Year Founded: 1997
Status: Acquired
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Oct 3, 2023
Deals
Lilly’s big step into radiopharma comes via $1.4B Point takeout
Looking beyond partnered programs, pharma acquires supply and manufacturing capabilities along with wholly-owned radioligand pipeline
BioCentury | Jun 22, 2023
Emerging Company Profile
ARTbio: manufacturing strategy to lead on lead-212 radiotherapies
With $23M seed and tech from alpha-emitter pioneers behind Xofigo, ARTbio to decentralize manufacturing of cancer radiotherapies
BioCentury | Feb 9, 2023
Management Tracks
Bill Anderson becomes CEO of Bayer
Plus: High leaving AskBio, and updates from Verily, PhRMA, MOMA and more
BioCentury | Oct 5, 2021
Management Tracks
Bernstein becomes CMO at BioMarin
Plus: Novavax, TPG, Noema, Syndax, Prothena, Annexon, ProQR and more
BioCentury | Jun 4, 2021
Deals
Acquisition of Babich-founded Noria helps Bayer pad radiopharmaceutical pipeline
A deal unveiled Thursday will help Bayer expand its footprint in alpha-emitting targeted radiopharmaceuticals. Bayer AG (Xetra:BAYN) announced it will acquire Noria Therapeutics Inc. and its
BioCentury | Jan 25, 2020
Product Development
Radiotherapy blasts forward
Who's doing what in next-generation targeted radiotherapies for cancer
BioCentury | Aug 22, 2016
Finance
Northern Lights 2.0
A deep dive into the to-do list for Scandinavia's new ecosystem creators
Items per page:
1 - 10 of 152